4
Changes in Ownership
Vaxcyte, Inc. Filed Acc 0001258693-26-000015
CHIEF EXECUTIVE OFFICER sold 18,198 shares at an average $55.63 ($1,012,375)
- CHIEF EXECUTIVE OFFICER acquired 16,198 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
PICKERING GRANT · CHIEF EXECUTIVE OFFICER
Table I: Non-derivative
7 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-07-27 | Exercise or conversion : show line 1 in the form 10b5-1 | +16,198 | $2.03 | $32,882 | 469,445 | D |
| 2026-07-27 | Sale : show line 2 in the form 10b5-1 | −11,783 | $55.52 | $654,133 | 457,662 | D |
| 2026-07-27 | Sale : show line 3 in the form 10b5-1 | −4,415 | $55.93 | $246,935 | 453,247 | D |
| 2026-07-27 | Sale : show line 4 in the form 10b5-1 | −756 | $55.52 | $41,970 | 133,459 | I |
| 2026-07-27 | Sale : show line 5 in the form 10b5-1 | −244 | $55.96 | $13,655 | 133,215 | I |
| 2026-07-27 | Sale : show line 6 in the form 10b5-1 | −622 | $55.54 | $34,546 | 133,593 | I |
| 2026-07-27 | Sale : show line 7 in the form 10b5-1 | −378 | $55.91 | $21,135 | 133,215 | I |
| Open-market sales · 18,198 sh · avg $55.63 · $1,012,375 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-07-27 | Exercise or conversion : show line 8 in the form 10b5-1 Stock Option (right to buy) | −16,198 | 137,000 | D |
Loading xslF345X06/wk-form4_1785269436.xml…